Brief: Matinas Biopharma Provides Business Update And 2022 Strategic Outlook
25/01/2022 13:03
Jan 25 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA PROVIDES BUSINESS UPDATE AND 2022
STRATEGIC
OUTLOOK
* MATINAS BIOPHARMA - COHORT 4 OF ENACT (ALL ORAL INDUCTION
REGIMEN) UNDERWAY WITH SIX PATIENTS ENROLLED AND TOPLINE INTERIM
DATA EXPECTED Q3 2022
* MATINAS BIOPHARMA - ENDED 2021 WITH $49.9 MILLION,
SUFFICIENT TO
FUND PLANNED OPERATIONS THROUGH 2023
Source text for Eikon: ID:nGNX4bJskC
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing